Protagonist Therapeutics, Inc. $PTGX Shares Sold by Great Lakes Advisors LLC

Great Lakes Advisors LLC lessened its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 36.0% during the 3rd quarter, Holdings Channel reports. The firm owned 89,171 shares of the company’s stock after selling 50,220 shares during the quarter. Great Lakes Advisors LLC’s holdings in Protagonist Therapeutics were worth $5,924,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. EFG Asset Management North America Corp. raised its position in shares of Protagonist Therapeutics by 1.1% during the 3rd quarter. EFG Asset Management North America Corp. now owns 82,639 shares of the company’s stock worth $5,493,000 after purchasing an additional 913 shares during the last quarter. Vanguard Personalized Indexing Management LLC purchased a new position in Protagonist Therapeutics during the third quarter worth $219,000. Resona Asset Management Co. Ltd. acquired a new position in shares of Protagonist Therapeutics in the third quarter worth $580,000. Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in shares of Protagonist Therapeutics by 123.1% in the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 90,317 shares of the company’s stock worth $6,000,000 after acquiring an additional 49,833 shares during the last quarter. Finally, Verdence Capital Advisors LLC purchased a new stake in shares of Protagonist Therapeutics in the third quarter valued at $202,000. 98.63% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on PTGX shares. Truist Financial lifted their price objective on Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. JPMorgan Chase & Co. lifted their price target on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Wedbush boosted their price objective on shares of Protagonist Therapeutics from $70.00 to $86.00 and gave the company an “outperform” rating in a research report on Tuesday, October 28th. Citigroup raised their target price on shares of Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Protagonist Therapeutics in a report on Monday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.77.

Insider Buying and Selling

In related news, CEO Dinesh V. Ph D. Patel sold 34,438 shares of Protagonist Therapeutics stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $82.48, for a total value of $2,840,446.24. Following the transaction, the chief executive officer owned 580,505 shares in the company, valued at approximately $47,880,052.40. This trade represents a 5.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Arturo Md Molina sold 13,151 shares of the business’s stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $82.42, for a total value of $1,083,905.42. Following the sale, the insider directly owned 84,115 shares of the company’s stock, valued at approximately $6,932,758.30. This trade represents a 13.52% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 165,167 shares of company stock valued at $13,732,039. 4.90% of the stock is currently owned by company insiders.

Protagonist Therapeutics Stock Performance

PTGX opened at $79.73 on Friday. Protagonist Therapeutics, Inc. has a 1 year low of $33.70 and a 1 year high of $96.54. The company’s 50 day simple moving average is $86.33 and its 200 day simple moving average is $72.53. The stock has a market capitalization of $4.98 billion, a PE ratio of 128.60 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). The company had revenue of $4.71 million for the quarter, compared to analysts’ expectations of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. As a group, sell-side analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.